CHYM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
["Good buy right now for an impatient trader: price is extremely oversold (RSI-6 ~16.8) and sitting just above a key support zone (S2 ~21.22), which often sets up a sharp reflex bounce.", "Options positioning is strongly risk-on (very low put/call ratios), reinforcing near-term bullish sentiment despite weak momentum.", "News flow is supportive (new large institutional stake disclosed + $200M buyback authorization) with a near-term catalyst window into the upcoming earnings event.", "Intellectia Proprietary Trading Signals", "- AI Stock Picker: No signal on given stock today.", "- SwingMax: No signal on given stock today."]
["Trend/momentum: Bearish near-term momentum\u2014MACD histogram is negative (-0.555) and expanding lower, signaling selling pressure is still active.", "Mean-reversion setup: RSI-6 at ~16.77 indicates an extreme oversold condition, which commonly precedes short, fast bounces even within downtrends.", "Levels: Current price 21.425 is just above S2 (21.22). A hold above this area favors a bounce attempt back toward S1 (22.659). Pivot resistance is much higher at ~24.987 (major upside checkpoint if a rebound gains traction).", "Moving averages: Converging MAs suggests the down move may be maturing, but the MACD implies the turn is not yet confirmed."]
["Capital return: Company announced a $200M share repurchase program (supports downside and improves per-share optics).", "Institutional interest: Ashton Thomas Private Wealth disclosed a new position of 5.13M shares ($129.1M), a notable confidence signal.", "Fund buying: Brown University disclosed 102,805 shares ($2.59M), adding incremental supportive sentiment.", "Event catalyst: Upcoming earnings release (calendar shows 2026-02-11 AH; company news cites 2026-02-25 call) can drive a volatility-driven upside move if results/guide land well."]
["Momentum still bearish: MACD is negative and worsening, so the stock can remain weak even while oversold.", "Business-model risk highlighted by analysts: Redburn notes partner-bank capacity limits could push more credit exposure onto Chime\u2019s balance sheet, potentially pressuring valuation multiples over time.", "High implied volatility: Market is pricing large moves; if earnings/news disappoint, downside can be swift."]
["Latest quarter (2025/Q3): Revenue grew to ~$543.5M, up ~28.84% YoY\u2014strong top-line momentum.", "Profitability trend improving: Net income was -$54.7M (still a loss) but improved ~148% YoY; EPS -$0.15 improved ~150% YoY, showing meaningful loss narrowing.", "Margins: Gross margin ~86.5% (slightly up YoY), indicating strong unit economics and scalability.", "Setup into next report: With revenue growth near ~30% and improving losses, the next earnings print is a key confirmation point."]
["Recent trend: Ratings remain broadly constructive, but with a more visible split\u2014new Neutral coverage (Redburn, PT $29) contrasts with bullish targets (Goldman Buy PT $30; B. Riley Buy PT $35; JPM/ Piper Overweight with PTs in the low-to-mid $30s).", "Price targets: Most cluster around $30\u2013$35, implying substantial upside from ~$21.43; the notable cautious outlier is UBS Neutral with PT $24.", "Wall Street pros: Strong revenue growth, improving margins/EBITDA trends, accelerating member growth in Q3, and operating leverage potential.", "Wall Street cons: Increasing lending/credit exposure risk and potential multiple compression if the business mix shifts toward balance-sheet risk."]
